Experts Say Interpretable Results Unlikely In Burzynski’s Antineoplastons Studies
Special Report: Politicla Pressure, System Loopholes, Enabled Burzynski To Avoid Usuals
Scientific Process
“Unfortunate Result Of Burzynski’s Practice Over Two Decades: Thousands Of Patients, Not Enough Data” To Determine Safety, Efficacy, FDA Says
Reviewers Note Major Flaws In Design Of Burzynski’s Trials
Interview: Burzynski Explains Why He Calls Treatment “Non-Toxic”
Case Study: The Post-Surgical Treatment Of A Child With Medulloblastoma At The Burzynski Clinic
Trending Stories
- How George Tidmarsh crossed the FDA-industry Rubicon
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
- How GLP-1RA drugs are reshaping patient physiology and the future of oncology
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval









